MARTINSRIED (dpa-AFX) - MorphoSys AG (MPSYY.PK) reported promising pre-clinical data on its proprietary drug candidate MOR208, a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. The pre-clinical data, which would be presented at the Annual Meeting of the American Society of Clinical Oncology on June 4, 2012, illustrate the potential for four different combination therapies with MOR208 in models of lymphoma.
The company added, 'These intriguing results provide a first rationale for MOR208 drug combinations which warrant further evaluation in clinical trials.' MOR208 is an Fc-engineered, humanized, anti-CD19 antibody with superior cytotoxicity in a number of in vitro and in vivo models of lymphoma and leukemia.
In June 2010, MorphoSys AG and Xencor reached a collaboration deal, which provided MorphoSys with an exclusive worldwide license to MOR208.
Copyright RTT News/dpa-AFX
© 2012 AFX News
